{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T23:27:37Z","timestamp":1773185257063,"version":"3.50.1"},"reference-count":90,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2016,3,31]],"date-time":"2016-03-31T00:00:00Z","timestamp":1459382400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2016,5,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Optimal use of current therapeutic opportunities for chronic myeloid leukemia patients requires integration of clinical and laboratory monitoring. Assessment of molecular response (MR) by real-time quantitative polymerase chain reaction is the most sensitive way to monitor tyrosine kinase inhibitor (TKI) treatment efficacy. Besides major molecular response, which has emerged as a safe haven for survival since the initial studies of first-line imatinib treatment, two additional MR milestones have recently been defined: early molecular response and deep molecular response. The achievement of such MR milestones within defined time points during therapy is thought to draw the ideal trajectory toward optimal long-term outcome and, possibly, successful treatment discontinuation. Sensitive and reproducible MR measurement and proper interpretation of MR results are therefore critical to correctly inform therapeutic decisions. In patients who do not achieve an optimal response to TKI therapy, BCR-ABL1 mutation screening should also be performed, because it may deliver useful information for TKI choice. This review aims to help clinicians apply and translate the latest response definitions and clinical recommendations into practice. We provide a critical update on how these recommendations have incorporated MR levels in the clinical decision algorithms and how detection of BCR-ABL1 mutations should be interpreted. We also include a practical guide for pathologists and molecular biologists to best perform molecular testing and for hematologists and oncologists to best integrate it into routine practice.<\/jats:p>","DOI":"10.1634\/theoncologist.2015-0337","type":"journal-article","created":{"date-parts":[[2016,4,1]],"date-time":"2016-04-01T03:44:20Z","timestamp":1459482260000},"page":"626-633","source":"Crossref","is-referenced-by-count":43,"title":["Best Practices in Chronic Myeloid Leukemia Monitoring and Management"],"prefix":"10.1093","volume":"21","author":[{"given":"Simona","family":"Soverini","sequence":"first","affiliation":[{"name":"Department of Experimental, Diagnostic and Specialty Medicine, Hematology\/Oncology \u201cL. e A. Ser\u00e0gnoli,\u201d University of Bologna, Bologna, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Caterina","family":"De Benedittis","sequence":"additional","affiliation":[{"name":"Department of Experimental, Diagnostic and Specialty Medicine, Hematology\/Oncology \u201cL. e A. Ser\u00e0gnoli,\u201d University of Bologna, Bologna, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manuela","family":"Mancini","sequence":"additional","affiliation":[{"name":"Department of Experimental, Diagnostic and Specialty Medicine, Hematology\/Oncology \u201cL. e A. Ser\u00e0gnoli,\u201d University of Bologna, Bologna, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giovanni","family":"Martinelli","sequence":"additional","affiliation":[{"name":"Department of Experimental, Diagnostic and Specialty Medicine, Hematology\/Oncology \u201cL. e A. Ser\u00e0gnoli,\u201d University of Bologna, Bologna, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2016,3,31]]},"reference":[{"key":"2021122309521651800_B1","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1056\/NEJM199904293401706","article-title":"Chronic myeloid leukemia","volume":"340","author":"Sawyers","year":"1999","journal-title":"N Engl J Med"},{"key":"2021122309521651800_B2","first-page":"85","article-title":"Chromosome studies on normal and leukemic human leukocytes","volume":"25","author":"Nowell","year":"1960","journal-title":"J Natl Cancer Inst"},{"key":"2021122309521651800_B3","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1038\/243290a0","article-title":"Letter: A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining","volume":"243","author":"Rowley","year":"1973","journal-title":"Nature"},{"key":"2021122309521651800_B4","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1126\/science.2408149","article-title":"Tyrosine kinase activity and transformation potency of bcr-abl oncogene products","volume":"247","author":"Lugo","year":"1990","journal-title":"Science"},{"key":"2021122309521651800_B5","doi-asserted-by":"crossref","first-page":"6558","DOI":"10.1073\/pnas.84.18.6558","article-title":"In vitro transformation of immature hematopoietic cells by the P210 BCR\/ABL oncogene product of the Philadelphia chromosome","volume":"84","author":"McLaughlin","year":"1987","journal-title":"Proc Natl Acad Sci USA"},{"key":"2021122309521651800_B6","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1126\/science.2406902","article-title":"Induction of chronic myelogenous leukemia in mice by the P210bcr\/abl gene of the Philadelphia chromosome","volume":"247","author":"Daley","year":"1990","journal-title":"Science"},{"key":"2021122309521651800_B7","doi-asserted-by":"crossref","first-page":"6649","DOI":"10.1073\/pnas.87.17.6649","article-title":"Induction of a chronic myelogenous leukemia-like syndrome in mice with v-abl and BCR\/ABL","volume":"87","author":"Kelliher","year":"1990","journal-title":"Proc Natl Acad Sci USA"},{"key":"2021122309521651800_B8","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1038\/344251a0","article-title":"Acute leukaemia in bcr\/abl transgenic mice","volume":"344","author":"Heisterkamp","year":"1990","journal-title":"Nature"},{"key":"2021122309521651800_B9","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1586\/14737140.8.6.853","article-title":"Imatinib mesylate for the treatment of chronic myeloid leukemia","volume":"8","author":"Soverini","year":"2008","journal-title":"Expert Rev Anticancer Ther"},{"key":"2021122309521651800_B10","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1038\/nm0596-561","article-title":"Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells","volume":"2","author":"Druker","year":"1996","journal-title":"Nat Med"},{"key":"2021122309521651800_B11","first-page":"1972","article-title":"Approval summary: Imatinib mesylate capsules for treatment of adult patients with newly diagnosed Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase","volume":"9","author":"Johnson","year":"2003","journal-title":"Clin Cancer Res"},{"key":"2021122309521651800_B12","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.leukres.2013.09.011","article-title":"Implications of BCR-ABL1 kinase domain-mediated resistance in chronic myeloid leukemia","volume":"38","author":"Soverini","year":"2014","journal-title":"Leuk Res"},{"key":"2021122309521651800_B13","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1007\/978-3-642-54490-3_2","article-title":"Dasatinib","volume":"201","author":"Lindauer","year":"2014","journal-title":"Recent Results Cancer Res"},{"key":"2021122309521651800_B14","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1007\/978-3-642-54490-3_3","article-title":"Nilotinib","volume":"201","author":"Ostendorf","year":"2014","journal-title":"Recent Results Cancer Res"},{"key":"2021122309521651800_B15","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1007\/978-3-642-54490-3_4","article-title":"Bosutinib: A novel second-generation tyrosine kinase inhibitor","volume":"201","author":"Isfort","year":"2014","journal-title":"Recent Results Cancer Res"},{"key":"2021122309521651800_B16","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1182\/blood-2013-06-511592","article-title":"Early response with dasatinib or imatinib in chronic myeloid leukemia: 3-year follow-up from a randomized phase 3 trial (DASISION)","volume":"123","author":"Jabbour","year":"2014","journal-title":"Blood"},{"key":"2021122309521651800_B17","doi-asserted-by":"crossref","first-page":"2771","DOI":"10.1182\/blood-2014-09-601674","article-title":"Phase 3 study of nilotinib vs imatinib in Chinese patients with newly diagnosed chronic myeloid leukemia in chronic phase: ENESTchina","volume":"125","author":"Wang","year":"2015","journal-title":"Blood"},{"key":"2021122309521651800_B18","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1111\/ejh.12423","article-title":"Dasatinib induces fast and deep responses in newly diagnosed chronic myeloid leukaemia patients in chronic phase: Clinical results from a randomised phase-2 study (NordCML006)","volume":"94","author":"Hjorth-Hansen","year":"2015","journal-title":"Eur J Haematol"},{"key":"2021122309521651800_B19","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.3324\/haematol.2015.129221","article-title":"Long-term outcome of a phase 2 trial with nilotinib 400 mg twice daily in first-line treatment of chronic myeloid leukemia","volume":"100","author":"Gugliotta","year":"2015","journal-title":"Haematologica"},{"issue":"suppl 2","key":"2021122309521651800_B20","doi-asserted-by":"crossref","first-page":"S149","DOI":"10.1007\/s00277-015-2318-y","article-title":"Management of adverse events associated with tyrosine kinase inhibitors in chronic myeloid leukemia","volume":"94","author":"Rea","year":"2015","journal-title":"Ann Hematol"},{"key":"2021122309521651800_B21","doi-asserted-by":"crossref","first-page":"394","DOI":"10.3816\/CLML.2010.n.073","article-title":"The durable clearance of the T315I BCR-ABL mutated clone in chronic phase chronic myelogenous leukemia patients on omacetaxine allows tyrosine kinase inhibitor rechallenge","volume":"10","author":"Nicolini","year":"2010","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"2021122309521651800_B22","doi-asserted-by":"crossref","first-page":"2573","DOI":"10.1182\/blood-2012-03-415307","article-title":"Phase 2 study of subcutaneous omacetaxine mepesuccinate after TKI failure in patients with chronic-phase CML with T315I mutation","volume":"120","author":"Cortes","year":"2012","journal-title":"Blood"},{"key":"2021122309521651800_B23","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1002\/ajh.23408","article-title":"Phase 2 study of subcutaneous omacetaxine mepesuccinate for chronic-phase chronic myeloid leukemia patients resistant to or intolerant of tyrosine kinase inhibitors","volume":"88","author":"Cortes","year":"2013","journal-title":"Am J Hematol"},{"key":"2021122309521651800_B24","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1634\/theoncologist.2013-0077","article-title":"U.S. Food and Drug Administration approval summary: Omacetaxine mepesuccinate as treatment for chronic myeloid leukemia","volume":"19","author":"Alvandi","year":"2014","journal-title":"The Oncologist"},{"key":"2021122309521651800_B25","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1002\/cncr.29240","article-title":"Final analysis of the efficacy and safety of omacetaxine mepesuccinate in patients with chronic- or accelerated-phase chronic myeloid leukemia: Results with 24 months of follow-up","volume":"121","author":"Cortes","year":"2015","journal-title":"Cancer"},{"key":"2021122309521651800_B26","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.ccr.2009.09.028","article-title":"AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance","volume":"16","author":"O\u2019Hare","year":"2009","journal-title":"Cancer Cell"},{"key":"2021122309521651800_B27","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1056\/NEJMoa1306494","article-title":"A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias","volume":"369","author":"Cortes","year":"2013","journal-title":"N Engl J Med"},{"key":"2021122309521651800_B28","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1007\/978-3-642-54490-3_5","article-title":"Ponatinib: A third-generation inhibitor for the treatment of CML","volume":"201","author":"Wehrle","year":"2014","journal-title":"Recent Results Cancer Res"},{"key":"2021122309521651800_B29","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1056\/NEJMc1315234","article-title":"Ponatinib in Philadelphia chromosome-positive leukemias","volume":"370","author":"Cortes","year":"2014","journal-title":"N Engl J Med"},{"key":"2021122309521651800_B30","doi-asserted-by":"crossref","first-page":"3322","DOI":"10.1182\/blood.V86.9.3322.bloodjournal8693322","article-title":"Homoharringtonine therapy induces responses in patients with chronic myelogenous leukemia in late chronic phase","volume":"86","author":"O\u2019Brien","year":"1995","journal-title":"Blood"},{"key":"2021122309521651800_B31","doi-asserted-by":"crossref","first-page":"4149","DOI":"10.1182\/blood.V93.12.4149","article-title":"Sequential homoharringtonine and interferon-alpha in the treatment of early chronic phase chronic myelogenous leukemia","volume":"93","author":"O\u2019Brien","year":"1999","journal-title":"Blood"},{"key":"2021122309521651800_B32","doi-asserted-by":"crossref","first-page":"3513","DOI":"10.1200\/JCO.2000.18.20.3513","article-title":"Homoharringtonine and low-dose cytarabine in the management of late chronic-phase chronic myelogenous leukemia","volume":"18","author":"Kantarjian","year":"2000","journal-title":"J Clin Oncol"},{"key":"2021122309521651800_B33","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1747-0285.2010.01054.x","article-title":"Structural mechanism of the Pan-BCR-ABL inhibitor ponatinib (AP24534): Lessons for overcoming kinase inhibitor resistance","volume":"77","author":"Zhou","year":"2011","journal-title":"Chem Biol Drug Des"},{"key":"2021122309521651800_B34","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1186\/s13045-015-0190-9","article-title":"Anti-leukemic activity of axitinib against cells harboring the BCR-ABL T315I point mutation","volume":"8","author":"Okabe","year":"2015","journal-title":"J Hematol Oncol"},{"key":"2021122309521651800_B35","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1038\/nature14119","article-title":"Axitinib effectively inhibits BCR-ABL1(T315I) with a distinct binding conformation","volume":"519","author":"Pemovska","year":"2015","journal-title":"Nature"},{"issue":"suppl 3","key":"2021122309521651800_B36","first-page":"S5","article-title":"Allogeneic bone marrow transplantation for CML: A report from the International Bone Marrow Transplant Registry","volume":"17","author":"Horowitz","year":"1996","journal-title":"Bone Marrow Transplant"},{"key":"2021122309521651800_B37","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1053\/j.seminhematol.2010.06.008","article-title":"Stem cell transplant for chronic myeloid leukemia in the imatinib era","volume":"47","author":"Radich","year":"2010","journal-title":"Semin Hematol"},{"key":"2021122309521651800_B38","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1182\/blood-2006-02-005686","article-title":"Evolving concepts in the management of chronic myeloid leukemia: Recommendations from an expert panel on behalf of the European LeukemiaNet","volume":"108","author":"Baccarani","year":"2006","journal-title":"Blood"},{"key":"2021122309521651800_B39","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.beha.2009.10.001","article-title":"Response definitions and European Leukemianet Management recommendations","volume":"22","author":"Baccarani","year":"2009","journal-title":"Best Pract Res Clin Haematol"},{"key":"2021122309521651800_B40","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1182\/blood-2013-05-501569","article-title":"European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013","volume":"122","author":"Baccarani","year":"2013","journal-title":"Blood"},{"issue":"suppl 2","key":"2021122309521651800_B41","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1053\/shem.2003.50044","article-title":"Molecular monitoring of chronic myeloid leukemia","volume":"40","author":"Hughes","year":"2003","journal-title":"Semin Hematol"},{"issue":"suppl 2","key":"2021122309521651800_B42","doi-asserted-by":"crossref","first-page":"S227","DOI":"10.1007\/s00277-015-2327-x","article-title":"Response-related predictors of survival in CML","volume":"94","author":"Hanfstein","year":"2015","journal-title":"Ann Hematol"},{"key":"2021122309521651800_B43","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1158\/1078-0432.CCR-13-1988","article-title":"Deep molecular response in chronic myeloid leukemia: The new goal of therapy?","volume":"20","author":"Mahon","year":"2014","journal-title":"Clin Cancer Res"},{"key":"2021122309521651800_B44","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V124.21.151.151","article-title":"Interim analysis of a pan European stop tyrosine kinase inhibitor trial in chronic myeloid leukemia: The EURO-SKI study","volume-title":"Paper presented at: 56th ASH Annual Meeting and Exposition","author":"Mahon","year":"2014"},{"key":"2021122309521651800_B45","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1038\/sj.leu.2401393","article-title":"Detection of BCR-ABL transcripts in chronic myeloid leukemia (CML) using an in situ RT-PCR assay","volume":"13","author":"Preudhomme","year":"1999","journal-title":"Leukemia"},{"key":"2021122309521651800_B46","doi-asserted-by":"crossref","first-page":"2318","DOI":"10.1038\/sj.leu.2403135","article-title":"Standardization and quality control studies of \u2018real-time\u2019 quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia\u2014a Europe Against Cancer program","volume":"17","author":"Gabert","year":"2003","journal-title":"Leukemia"},{"key":"2021122309521651800_B47","doi-asserted-by":"crossref","first-page":"2474","DOI":"10.1038\/sj.leu.2403136","article-title":"Evaluation of candidate control genes for diagnosis and residual disease detection in leukemic patients using \u2018real-time\u2019 quantitative reverse-transcriptase polymerase chain reaction (RQ-PCR)\u2014a Europe against cancer program","volume":"17","author":"Beillard","year":"2003","journal-title":"Leukemia"},{"key":"2021122309521651800_B48","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1038\/leu.2015.29","article-title":"Laboratory recommendations for scoring deep molecular responses following treatment for chronic myeloid leukemia","volume":"29","author":"Cross","year":"2015","journal-title":"Leukemia"},{"key":"2021122309521651800_B49","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1182\/blood-2006-01-0092","article-title":"Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: Review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results","volume":"108","author":"Hughes","year":"2006","journal-title":"Blood"},{"key":"2021122309521651800_B50","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.beha.2009.04.001","article-title":"Standardisation of molecular monitoring for chronic myeloid leukaemia","volume":"22","author":"Cross","year":"2009","journal-title":"Best Pract Res Clin Haematol"},{"key":"2021122309521651800_B51","doi-asserted-by":"crossref","first-page":"1957","DOI":"10.1038\/leu.2009.168","article-title":"Harmonization of molecular monitoring of CML therapy in Europe","volume":"23","author":"M\u00fcller","year":"2009","journal-title":"Leukemia"},{"key":"2021122309521651800_B52","volume-title":"National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines). Chronic Myelogenous Leukemia. Version 1. 2016"},{"key":"2021122309521651800_B53","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1373\/clinchem.2012.196477","article-title":"Establishment and validation of analytical reference panels for the standardization of quantitative BCR-ABL1 measurements on the international scale","volume":"59","author":"White","year":"2013","journal-title":"Clin Chem"},{"key":"2021122309521651800_B54","doi-asserted-by":"crossref","first-page":"e111","DOI":"10.1182\/blood-2010-06-291641","article-title":"Establishment of the first World Health Organization International Genetic Reference Panel for quantitation of BCR-ABL mRNA","volume":"116","author":"White","year":"2010","journal-title":"Blood"},{"key":"2021122309521651800_B55","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1002\/ajh.21457","article-title":"Technical aspects and clinical applications of measuring BCR-ABL1 transcripts number in chronic myeloid leukemia","volume":"84","author":"Foroni","year":"2009","journal-title":"Am J Hematol"},{"key":"2021122309521651800_B56","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1093\/clinchem\/48.10.1647","article-title":"Stability of endogenous and added RNA in blood specimens, serum, and plasma","volume":"48","author":"Tsui","year":"2002","journal-title":"Clin Chem"},{"key":"2021122309521651800_B57","doi-asserted-by":"crossref","first-page":"2395","DOI":"10.1038\/sj.leu.2402734","article-title":"Improvement of molecular monitoring of residual disease in leukemias by bedside RNA stabilization","volume":"16","author":"M\u00fcller","year":"2002","journal-title":"Leukemia"},{"key":"2021122309521651800_B58","first-page":"1471","article-title":"The impact of RNA stabilization on minimal residual disease assessment in chronic myeloid leukemia","volume":"90","author":"Th\u00f6rn","year":"2005","journal-title":"Haematologica"},{"key":"2021122309521651800_B59","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1016\/j.leukres.2005.08.027","article-title":"Assessment of a new RNA stabilizing reagent (Tempus Blood RNA) for minimal residual disease in onco-hematology using the EAC protocol","volume":"30","author":"Prezeau","year":"2006","journal-title":"Leuk Res"},{"key":"2021122309521651800_B60","doi-asserted-by":"crossref","first-page":"4437","DOI":"10.1182\/blood-2008-06-162388","article-title":"European LeukemiaNet criteria for failure or suboptimal response reliably identify patients with CML in early chronic phase treated with imatinib whose eventual outcome is poor","volume":"112","author":"Marin","year":"2008","journal-title":"Blood"},{"key":"2021122309521651800_B61","doi-asserted-by":"crossref","first-page":"8912","DOI":"10.1158\/0008-5472.CAN-05-0076","article-title":"Bcr-Abl expression levels determine the rate of development of resistance to imatinib mesylate in chronic myeloid leukemia","volume":"65","author":"Barnes","year":"2005","journal-title":"Cancer Res"},{"key":"2021122309521651800_B62","doi-asserted-by":"crossref","first-page":"2371","DOI":"10.1182\/blood.V86.6.2371.bloodjournal8662371","article-title":"Increase of bcr-abl chimeric mRNA expression in tumor cells of patients with chronic myeloid leukemia precedes disease progression","volume":"86","author":"Gaiger","year":"1995","journal-title":"Blood"},{"key":"2021122309521651800_B63","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1038\/leu.2010.101","article-title":"BCR and BCR-ABL regulation during myeloid differentiation in healthy donors and in chronic phase\/blast crisis CML patients","volume":"24","author":"Marega","year":"2010","journal-title":"Leukemia"},{"key":"2021122309521651800_B64","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.ccr.2005.10.015","article-title":"The tumor suppressor PP2A is functionally inactivated in blast crisis CML through the inhibitory activity of the BCR\/ABL-regulated SET protein","volume":"8","author":"Neviani","year":"2005","journal-title":"Cancer Cell"},{"key":"2021122309521651800_B65","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1007\/s11899-012-0114-5","article-title":"Genetic mechanisms of chronic myeloid leukemia blastic transformation","volume":"7","author":"Skorski","year":"2012","journal-title":"Curr Hematol Malig Rep"},{"key":"2021122309521651800_B66","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1182\/blood-2007-03-078303","article-title":"High levels of the BCR\/ABL oncoprotein are required for the MAPK-hnRNP-E2 dependent suppression of C\/EBPalpha-driven myeloid differentiation","volume":"110","author":"Chang","year":"2007","journal-title":"Blood"},{"key":"2021122309521651800_B67","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.3324\/haematol.2008.001214","article-title":"Treatment of chronic myeloid leukemia in blast crisis","volume":"93","author":"Hehlmann","year":"2008","journal-title":"Haematologica"},{"key":"2021122309521651800_B68","doi-asserted-by":"crossref","first-page":"743","DOI":"10.3324\/haematol.2009.006999","article-title":"Sustained durability of responses and improved progression-free and overall survival with imatinib treatment for accelerated phase and blast crisis chronic myeloid leukemia: Long-term follow-up of the STI571 0102 and 0109 trials","volume":"94","author":"Silver","year":"2009","journal-title":"Haematologica"},{"key":"2021122309521651800_B69","doi-asserted-by":"crossref","first-page":"7374","DOI":"10.1158\/1078-0432.CCR-06-1516","article-title":"Contribution of ABL kinase domain mutations to imatinib resistance in different subsets of Philadelphia-positive patients: By the GIMEMA Working Party on Chronic Myeloid Leukemia","volume":"12","author":"Soverini","year":"2006","journal-title":"Clin Cancer Res"},{"key":"2021122309521651800_B70","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.2217\/pgs.12.103","article-title":"Advances in treatment of chronic myeloid leukemia with tyrosine kinase inhibitors: The evolving role of Bcr-Abl mutations and mutational analysis","volume":"13","author":"Soverini","year":"2012","journal-title":"Pharmacogenomics"},{"key":"2021122309521651800_B71","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1182\/blood-2010-12-326405","article-title":"BCR-ABL kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: Recommendations from an expert panel on behalf of European LeukemiaNet","volume":"118","author":"Soverini","year":"2011","journal-title":"Blood"},{"key":"2021122309521651800_B72","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1002\/ajh.22272","article-title":"BCR-ABL1 kinase domain mutations: Methodology and clinical evaluation","volume":"87","author":"Alikian","year":"2012","journal-title":"Am J Hematol"},{"key":"2021122309521651800_B73","doi-asserted-by":"crossref","first-page":"1634","DOI":"10.1182\/blood-2013-03-487728","article-title":"Unraveling the complexity of tyrosine kinase inhibitor-resistant populations by ultra-deep sequencing of the BCR-ABL kinase domain","volume":"122","author":"Soverini","year":"2013","journal-title":"Blood"},{"key":"2021122309521651800_B74","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1007\/s00432-014-1845-6","article-title":"Next-generation deep sequencing improves detection of BCR-ABL1 kinase domain mutations emerging under tyrosine kinase inhibitor treatment of chronic myeloid leukemia patients in chronic phase","volume":"141","author":"Machova Polakova","year":"2015","journal-title":"J Cancer Res Clin Oncol"},{"key":"2021122309521651800_B75","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1016\/j.ejca.2013.11.030","article-title":"Rapid identification of compound mutations in patients with Philadelphia-positive leukaemias by long-range next generation sequencing","volume":"50","author":"Kastner","year":"2014","journal-title":"Eur J Cancer"},{"key":"2021122309521651800_B76","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1634\/theoncologist.2010-0388","article-title":"Choosing the best second-line tyrosine kinase inhibitor in imatinib-resistant chronic myeloid leukemia patients harboring Bcr-Abl kinase domain mutations: How reliable is the IC50?","volume":"16","author":"Soverini","year":"2011","journal-title":"The Oncologist"},{"key":"2021122309521651800_B77","doi-asserted-by":"crossref","first-page":"e51","DOI":"10.1200\/JCO.2006.08.9128","article-title":"Presence or the emergence of a F317L BCR-ABL mutation may be associated with resistance to dasatinib in Philadelphia chromosome-positive leukemia","volume":"24","author":"Soverini","year":"2006","journal-title":"J Clin Oncol"},{"key":"2021122309521651800_B78","doi-asserted-by":"crossref","first-page":"401","DOI":"10.3324\/haematol.10822","article-title":"Resistance to dasatinib in Philadelphia-positive leukemia patients and the presence or the selection of mutations at residues 315 and 317 in the BCR-ABL kinase domain","volume":"92","author":"Soverini","year":"2007","journal-title":"Haematologica"},{"key":"2021122309521651800_B79","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/S1470-2045(07)70078-5","article-title":"Second-line treatment with dasatinib in patients resistant to imatinib can select novel inhibitor-specific BCR-ABL mutants in Ph+ ALL","volume":"8","author":"Soverini","year":"2007","journal-title":"Lancet Oncol"},{"key":"2021122309521651800_B80","doi-asserted-by":"crossref","first-page":"2037","DOI":"10.1182\/blood-2009-01-197715","article-title":"Long-term outcome of patients with chronic myeloid leukemia treated with second-generation tyrosine kinase inhibitors after imatinib failure is predicted by the in vitro sensitivity of BCR-ABL kinase domain mutations","volume":"114","author":"Jabbour","year":"2009","journal-title":"Blood"},{"key":"2021122309521651800_B81","doi-asserted-by":"crossref","first-page":"4204","DOI":"10.1200\/JCO.2009.21.8230","article-title":"Impact of baseline BCR-ABL mutations on response to nilotinib in patients with chronic myeloid leukemia in chronic phase","volume":"27","author":"Hughes","year":"2009","journal-title":"J Clin Oncol"},{"key":"2021122309521651800_B82","doi-asserted-by":"crossref","first-page":"4944","DOI":"10.1182\/blood-2009-04-214221","article-title":"Dasatinib treatment of chronic-phase chronic myeloid leukemia: Analysis of responses according to preexisting BCR-ABL mutations","volume":"114","author":"M\u00fcller","year":"2009","journal-title":"Blood"},{"key":"2021122309521651800_B83","doi-asserted-by":"crossref","first-page":"2378","DOI":"10.1182\/blood-2007-06-096396","article-title":"In vivo kinetics of kinase domain mutations in CML patients treated with dasatinib after failing imatinib","volume":"111","author":"Khorashad","year":"2008","journal-title":"Blood"},{"key":"2021122309521651800_B84","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1200\/JCO.2008.19.8853","article-title":"Activity of bosutinib, dasatinib, and nilotinib against 18 imatinib-resistant BCR\/ABL mutants","volume":"27","author":"Redaelli","year":"2009","journal-title":"J Clin Oncol"},{"key":"2021122309521651800_B85","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/j.ccr.2014.07.006","article-title":"BCR-ABL1 compound mutations combining key kinase domain positions confer clinical resistance to ponatinib in Ph chromosome-positive leukemia","volume":"26","author":"Zabriskie","year":"2014","journal-title":"Cancer Cell"},{"key":"2021122309521651800_B86","doi-asserted-by":"crossref","first-page":"4567","DOI":"10.1182\/blood-2011-05-355594","article-title":"Safety and efficacy of bosutinib (SKI-606) in chronic phase Philadelphia chromosome-positive chronic myeloid leukemia patients with resistance or intolerance to imatinib","volume":"118","author":"Cortes","year":"2011","journal-title":"Blood"},{"key":"2021122309521651800_B87","doi-asserted-by":"crossref","first-page":"3486","DOI":"10.1200\/JCO.2011.38.7522","article-title":"Bosutinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: Results from the BELA trial","volume":"30","author":"Cortes","year":"2012","journal-title":"J Clin Oncol"},{"key":"2021122309521651800_B88","doi-asserted-by":"crossref","first-page":"3403","DOI":"10.1182\/blood-2011-11-390120","article-title":"Bosutinib is active in chronic phase chronic myeloid leukemia after imatinib and dasatinib and\/or nilotinib therapy failure","volume":"119","author":"Khoury","year":"2012","journal-title":"Blood"},{"key":"2021122309521651800_B89","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1002\/ajh.23728","article-title":"Bosutinib efficacy and safety in chronic phase chronic myeloid leukemia after imatinib resistance or intolerance: Minimum 24-month follow-up","volume":"89","author":"Gambacorti-Passerini","year":"2014","journal-title":"Am J Hematol"},{"key":"2021122309521651800_B90","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1002\/ajh.24034","article-title":"Long-term efficacy and safety of bosutinib in patients with advanced leukemia following resistance\/intolerance to imatinib and other tyrosine kinase inhibitors","volume":"90","author":"Gambacorti-Passerini","year":"2015","journal-title":"Am J Hematol"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1634\/theoncologist.2015-0337","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1634\/theoncologist.2015-0337","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/21\/5\/626\/41874471\/oncolo_21_5_626.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/21\/5\/626\/41874471\/oncolo_21_5_626.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,24]],"date-time":"2021-12-24T04:03:54Z","timestamp":1640318634000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/21\/5\/626\/6401569"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,3,31]]},"references-count":90,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2016,3,31]]},"published-print":{"date-parts":[[2016,5,1]]}},"URL":"https:\/\/doi.org\/10.1634\/theoncologist.2015-0337","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2016,5,1]]},"published":{"date-parts":[[2016,3,31]]}}}